Stephanie Licata

426 total citations
14 papers, 284 citations indexed

About

Stephanie Licata is a scholar working on Pathology and Forensic Medicine, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Stephanie Licata has authored 14 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pathology and Forensic Medicine, 10 papers in Oncology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Stephanie Licata's work include Polyomavirus and related diseases (10 papers), Multiple Sclerosis Research Studies (9 papers) and Acute Lymphoblastic Leukemia research (6 papers). Stephanie Licata is often cited by papers focused on Polyomavirus and related diseases (10 papers), Multiple Sclerosis Research Studies (9 papers) and Acute Lymphoblastic Leukemia research (6 papers). Stephanie Licata collaborates with scholars based in United States, Italy and Switzerland. Stephanie Licata's co-authors include María Trojano, Pei‐Ran Ho, John F. Neil, Stephen May, Nolan Campbell, Jonathan M. Himmelhoch, Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl and Tim Spelman and has published in prestigious journals such as American Journal of Psychiatry, Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Stephanie Licata

14 papers receiving 271 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephanie Licata United States 7 175 110 75 52 45 14 284
Gabrielle Macaron United States 10 200 1.1× 32 0.3× 37 0.5× 77 1.5× 15 0.3× 28 301
Trudy L. Campbell Canada 5 313 1.8× 41 0.4× 50 0.7× 59 1.1× 19 0.4× 7 358
Alexander Stahmann Germany 12 315 1.8× 62 0.6× 39 0.5× 108 2.1× 24 0.5× 38 395
Federica Ranzato Italy 9 110 0.6× 23 0.2× 100 1.3× 66 1.3× 21 0.5× 15 262
Josephine Baker Australia 7 187 1.1× 29 0.3× 29 0.4× 37 0.7× 9 0.2× 10 241
Kerstin Hellwig Germany 8 160 0.9× 34 0.3× 16 0.2× 60 1.2× 26 0.6× 33 238
Matthias Kant Denmark 10 384 2.2× 98 0.9× 20 0.3× 103 2.0× 45 1.0× 23 455
Nina Schäffler Germany 7 212 1.2× 36 0.3× 12 0.2× 48 0.9× 16 0.4× 7 300
Geraldine Luetic Argentina 8 182 1.0× 38 0.3× 9 0.1× 65 1.3× 17 0.4× 13 204
Dorota Dunin-Wąsowicz Poland 9 29 0.2× 131 1.2× 79 1.1× 24 0.5× 17 0.4× 21 494

Countries citing papers authored by Stephanie Licata

Since Specialization
Citations

This map shows the geographic impact of Stephanie Licata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephanie Licata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephanie Licata more than expected).

Fields of papers citing papers by Stephanie Licata

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephanie Licata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephanie Licata. The network helps show where Stephanie Licata may publish in the future.

Co-authorship network of co-authors of Stephanie Licata

This figure shows the co-authorship network connecting the top 25 collaborators of Stephanie Licata. A scholar is included among the top collaborators of Stephanie Licata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephanie Licata. Stephanie Licata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Nicholas, Richard, et al.. (2022). 014  Long-term effectiveness of natalizumab for RRMS: UK and global interim results from TYSABRI observational program. Journal of Neurology Neurosurgery & Psychiatry. 93(6). A18.1–A18. 1 indexed citations
2.
Ryerson, Lana Zhovtis, Robert T. Naismith, Lauren Krupp, et al.. (2021). No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in MS PATHS (1964). Neurology. 96(15_supplement). 1 indexed citations
3.
Trojano, María, Lluís Ramió‐Torrentà, Catherine Lubetzki, et al.. (2021). A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal. 27(14). 2240–2253. 35 indexed citations
4.
Butzkueven, Helmut, Ludwig Kappos, Tim Spelman, et al.. (2021). No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). Therapeutic Advances in Neurological Disorders. 14. 4203323546–4203323546. 9 indexed citations
5.
Butzkueven, Helmut, Stephanie Licata, Douglas Jeffery, et al.. (2020). Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. BMJ Open. 10(10). e038861–e038861. 17 indexed citations
6.
Butzkueven, Helmut, Ludwig Kappos, Heinz Wiendl, et al.. (2020). Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Journal of Neurology Neurosurgery & Psychiatry. 91(6). 660–668. 99 indexed citations
7.
Giovannoni, Gavin, Ludwig Kappos, Joseph R. Berger, et al.. (2020). Updated Incidence of Natalizumab-associated Progressive Multifocal Leukoencephalopathy (PML) and Its Relationship with Natalizumab Exposure Over Time (2815). Neurology. 94(15_supplement). 6 indexed citations
8.
Wiendl, Heinz, Tim Spelman, Helmut Butzkueven, et al.. (2020). Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. Multiple Sclerosis Journal. 27(5). 719–728. 21 indexed citations
9.
Butzkueven, Helmut, María Trojano, Ludwig Kappos, et al.. (2020). Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP). Multiple Sclerosis Journal. 27(3). 410–419. 7 indexed citations
10.
Giovannoni, Gavin, Ludwig Kappos, Joseph R. Berger, et al.. (2019). Incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time. Revue Neurologique. 175. S96–S97. 3 indexed citations
11.
Kappos, Ludwig, Helmut Butzkueven, Tim Spelman, et al.. (2019). Real-world data from over 10 years in the TYSABRI® Observational Program: Long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients. Revue Neurologique. 175. S101–S102. 5 indexed citations
12.
Butzkueven, Helmut, Douglas Jeffery, Douglas L. Arnold, et al.. (2018). 086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study. Journal of Neurology Neurosurgery & Psychiatry. 89(6). A35.1–A35. 1 indexed citations
13.
Licata, Stephanie, Helmut Butzkueven, Douglas Jeffery, et al.. (2017). Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study. Journal of the Neurological Sciences. 381. 246–246. 1 indexed citations
14.
Himmelhoch, Jonathan M., et al.. (1980). Age, dementia, dyskinesias, and lithium response. American Journal of Psychiatry. 137(8). 941–945. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabrielle Macaron Breakdown of academic impact, for papers by Trudy L. Campbell Breakdown of academic impact, for papers by Alexander Stahmann Breakdown of academic impact, for papers by Federica Ranzato Breakdown of academic impact, for papers by Josephine Baker Breakdown of academic impact, for papers by Kerstin Hellwig Breakdown of academic impact, for papers by Matthias Kant Breakdown of academic impact, for papers by Nina Schäffler Breakdown of academic impact, for papers by Geraldine Luetic Breakdown of academic impact, for papers by Dorota Dunin-Wąsowicz
Rankless by CCL
2026